Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Solriamfetol in Binge eating disorder. The expected timing is based on the latest available company guidance and may change.
ENGAGE trial. 4/1/24- Ph3 initiated. 5/5/25- Topline data in 2026. 11/30/25:- Topline results from the ENGAGE Ph3 BED trial continue to be expected in 2026. 02/23/26:- ENGAGE Phase 3 binge eating disorder trial topline results now expected in second half 2026. 05/04/26:- ENGAGE Phase 3 binge eating disorder trial ongoing; topline results remain expected in the second half of 2026.
Verification
Confirm timing and program details against the company announcement or filing.